About the Company
BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NTGN News
A Look Into BioNTech Inc's Price Over Earnings
In the current session, BioNTech Inc. (NASDAQ:BNTX ... Chinese Tech Companies Forced To Think Outside The Box To Overcome US Chip Ban In The Race For AI Supremacy Compared to the aggregate ...
BioNTech Gains as Vaccine Maker Has Profit on Cost-Sharing
The US depositary ... vaccine rival Moderna Inc. have both reined in expectations for Covid-related sales in recent weeks. The pandemic shots were both Moderna’s and BioNTech’s first products ...
COVID Vaccines Reduce Risk of Heart Failure, Clots
People who got COVID-19 vaccines had a reduced risk of heart failure, compared to people who didn’t get vaccinated, according ...
Pfizer/BioNTech dose first US patients with COVID-19 vaccine
Pfizer and its development partner BioNTech have begun dosing the first people in the US with a potential COVID-19 vaccine, as part of their ongoing phase 1/2 clinical trial. The companies ...
BioNTech Announces Planned Retirement of Sean Marett
Sean Marett joined BioNTech as a member of the Management Board in 2012. He has played a crucial role in the Company’s growth and global expansion, overseeing two key areas: business development and ...
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also ...
COVID-19 Vaccine Update – It’s All Eyes on the FDA and BioNTech/Pfizer Inc.
Approval would mean that BioNTech/Pfizer Inc. will be able to begin distributing vaccines as early as the weekend. Unfortunately, supply chain issues have meant that vaccine production for the ...
Moderna, BioNTech Stocks Rise on New mRNA Possibilities
Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest ...
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pfizer, BioNTech seek US okay for Omicron BA.4/BA.5 booster
According to Pfizer/BioNTech, preclinical data has shown that a booster dose with the BA.4/BA.5-adapted bivalent vaccine generated a strong neutralising antibody response against Omicron BA.1, BA ...
Loading the latest forecasts...